Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679061 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2LMNAFPR2PROKR1RAB9A | |
| SCHEMBL22436773 | 0.79 | CSNK2A1 (0.32) | — | |
| SCHEMBL30679081 | 0.79 | CSNK2A1 (0.32) | — | |
| SCHEMBL14043734 | 0.76 | CSNK2A1 (0.36) | SMN1; SMN2LMNARAB9A | |
| SCHEMBL30679115 | 0.76 | CSNK2A1 (0.36) | SMN1; SMN2LMNARAB9A | |
| SCHEMBL22436700 | 0.75 | CSNK2A1 (0.36) | SMN1; SMN2LMNARAB9A | |
| SCHEMBL30679098 | 0.75 | CSNK2A1 (0.36) | SMN1; SMN2LMNARAB9A | |
| SCHEMBL30679095 | 0.72 | CSNK2A1 (0.35) | — | |
| SCHEMBL22436737 | 0.72 | CSNK2A1 (0.35) | — | |
| SCHEMBL24593558 | 0.71 | NPC1 (0.31) | SMN1; SMN2LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440923-B2 | Substituted macrocyclic indole derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | disclosed |
| EP-3710451-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440923-B2 | Substituted macrocyclic indole derivatives | FOXM1, CCND2, CCNI | SMN1; SMN2 4020/4885LMNA 819/4885FPR2 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.